


HIGHLIGHTS

29-30TH JANUARY 2019 | WASHINGTON D.C, USA

PHAGE
FUTURES
CONGRESS



The inaugural Phage Futures Congress was the first kind to discuss how to translate phage-based application on to clinically and commercially viable therapeutics. The meeting brought together a wide range of participants, including representatives of established biotech companies (from human and animal applications), new adopters, key academic researchers and large pharma. The diverse content made for two full days of highly engaging discussions on how to move phage therapy forward.

Great overview of the field, key players were present, strong opening with focus on patient to orient the audience what matters

Dirk Gevers , J&J

184

Attendees

28+

Phage leading
speakers

28

Research
posters

Key discussions included:

-  Natural vs engineered Phage
-  Clinical trial vs compassionate use
-  Fixed phage cocktails vs personalized phage

EXPERT SPEAKER FACULTY



Dr Steffanie Strathdee
Associate Dean of Global
Health Sciences
University of California San Diego



Professor Thomas Patterson
University of California
San Diego School of Medicine



Dr Carl Merril
CSO and founder
Adaptive Phage Therapeutics



Scott Stibitz
Microbiologist
Center for Biologics Evaluation
and Research FDA



Professor Martha Clokie
Professor of Microbiology
University of Leicester



Cara Fiore
Microbiologist
Center for Biologics
Evaluation and Research FDA



Dr Biswajit Biswas
Chief, Division of Bacteriophage Science,
Biological Defense Research Directorate,
US Naval Medical Research Center



Dr Joe Campbell
Research Resources
Project Officer
NIH (NIAID)



Dr Magda Barbu
Senior Director, Synthetic Biology
C3J therapeutics



Dr Shawna McCallin
Project Leader
PhageForward



Xavier Dupontet
CEO
Eligo Bioscience



Dr Brian Varnum
Chief Development Officer
C3J therapeutics



Dr David Harper
CEO and CSO
Evolution Biotechnologies



Dr Tobi Nagel
Founder & President
Phages for Global Health



Greg Merril
CEO and founder
Adaptive Phage Therapeutics



Dr Betty Kutter
Head of Bacteriophage Lab
Evergreen State College



Dr Carl Balibar
Principal Scientist
Merck



Dr Catherine Loc-Carrillo
Internal Medicine - Research
Assistant Professor
University of Utah



Dr Derek Holman
Stanford University



Dr Nick Conley
Principal Scientist
Locus Biosciences



Dr Benjamin Chan
Yale University



Dr Chandrabali Ghose
Founder and CEO
Bioharmony Therapeutics



Dr Kevin Yehl
Lead Phage
Researcher
MIT



Dr Carrie-Lynn Langlais Furr
VP of Regulatory Affairs
AmpliPhi Biosciences



Dr Jarek Dastychny,
CEO
Proteon
Pharmaceuticals




Dr Mark Engel,
CEO
Phagelux



Dr Laurent Bretaudeau
Head of R&D
Clean Cells

WHO ATTENDED



 **21**


countries represented

USA	Canada	France	Netherlands
UK	Colombia	Israel	Norway
Austria	Czech Republic	Japan	Portugal
Australia	Denmark	China	Sweden
Belgium	Finland	Korea	Slovenia
Switzerland			



CRITICAL THEMES DISCUSSED AT PHAGE FUTURES

- One-size-fits-all or personalized phage therapy: both strategies have merit
- Natural vs. synthetically engineered phages: room for both
- Phages for acute infections vs. chronic, microbiome-linked disease: both are being pursued
- Clinical safety trials: general trust in the safety of phages, now time for clinical efficacy trials
- Clinical efficacy trials: a major hurdle to commercialization that has yet to be surmounted for phage therapy
- The FDA is supportive of phage therapy clinical efficacy trials and invites companies to reach out to them early
- Compassionate phage therapy: enormous potential benefit for individual patients but NOT sustainable or scalable



Read more about these key
themes in the full event
report written for Phage
Futures by Phage Directory

**CLICK
HERE**

WHAT TO EXPECT AT PHAGE FUTURES

First conference really focused on moving phage therapy and phage-related technologies forward. A great combination of regulatory, commercial, and scientific presentations.

Shawna McCallin, Phage Forward



The event was helpful for me to evidence the advances on Phages technology and the big impact we will have when this technology passes regulatory challenges. - Paula Barngrover, Premex



Wide variety of subjects. - Adam Glass, FDA



I thought the meeting was well put together with a good variety of presenters from academia, government, and industry. I would encourage other phage experts to attend future meetings. - Catherine Loc-Carrillo, University of Utah



This was an excellent gathering of people working with phage from academia, industry and regulatory agencies. I enjoyed meeting people and learned ALOT! - Bryan Gibb, New York Institute of Technology



Great presentations and diversity. - Sandra Giannini, GSK



Balance between industrial view and academic view on phage therapy. - Yun Je Sung, Kaist



The conference brought together a number of the leaders in efforts to develop the potential of the bacterial viruses to serve as antibacterial therapeutic agents. - Carl Merrill, APT



Excitement of the Phage society. - Hitoshi Kudo, Mitsui & Co., Ltd




This conference was so unique since it represented so many different sectors of the economy, including academic, regulatory, nonprofit, small biotech, and big pharma. - Travis Mavrich, University of Pittsburgh



As a NIAID program officer interested in promoting the development of phage therapy this was a good meeting. It provided a chance to hear about the current progress and challenges in phage therapy. It also provided me with a chance to discuss the resources NIAID has to offer to help those working to develop phage therapy. - Joseph Campbell, NIH


AUDIENCE BREAKDOWN

ATTENDEES BY COMPANY CATEGORY



- Service Providers
- Biotech & Pharma
- Academia & Government Institutions

ATTENDEES BY JOB FUNCTION



- Researchers/Academics
- Business Development
- CEO/CMO/CSO/Founder
- Department Head
- Director
- Clinician/Physician
- Consultant
- Professor
- Staff Fellow
- Quality (QA/QC)
- Scientist/Senior Scientist/Principal Scientist

SAVE THE DATE

PHAGE FUTURES EUROPE

Phage Futures Europe

September 25-26th, 2019 | Belgium
www.phage-futures-europe.com

PHAGE FUTURES CONGRESS

Phage Futures Congress

January 29-30th, 2020
 Washington D.C | USA
www.phage-futures.com

WITH THANKS TO OUR...

EVENT PARTNERS

Phagelux



Cellexus

Proteon 
Pharmaceuticals

MEDIA PARTNERS


 **Phage** Directory

 **IIDS**
Infectious Diseases Society of America

 **viruses**
an Open Access Journal by MDPI

PHAGE FUTURES SERIES

PHAGE FUTURES EUROPE



2019 September 25-26th | Belgium

Confirmed Speaker



Dr Ard Struijs from Erasmus University Medical Center will be providing a Physician's perspective about administering phage therapy.

Focusing on:

-  Magisterial Phage: Who, What and Why?
-  Learn from the Belgium early adopters.

PARTNER WITH US

For details on how you can partner with us on our next congress, please contact:

Tom Ledward | Commercial Manager
Partner@kisacoresearch.com | + 44 203 696 2920

PHAGE FUTURES CONGRESS



2020 January 29-30th | Washington D.C. | USA

Confirmed Speakers



Dr Cara Fiore
Microbiologist
Center for Biologics
Evaluation and Research
FDA



Dr Carl Balibar
Principal Scientist
Merck



Dr Biswajit Biswas
Chief, Division of
Bacteriophage Science,
Biological Defense
Research Directorate
US Naval Medical
Research Center

Focusing on:

-  Developments within phage applications across acute and chronic illnesses
-  Regulatory discussions, including clinical trial landscape updates
-  Understanding of the animal health phage applications can translate into progressing human phage therapy commercialisation